Viatris news in 2026: 13 dated events
The latest Viatris event on this page is dated Oct 30, 2026. prnewswire.com reported: Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.
Public (VTRS)Pharmaceutical Manufacturing10,000+ employeesviatris.comLinkedIn
Get Viatris' live signals in Claude or ChatGPT, or by API
What changed at Viatris this week? Use Autobound signals for viatris.com.- Dated events
- 15
- Last 90 days
- 8
- Latest
- Oct 30, 2026
Source: Autobound Signal API · 73 signals tracked for Viatris · updated
News · latest 10
Latest Viatris news
Showing 10 of 15 dated events. The Signal API returns all of them.
Get them with one API call- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.Viatris commenced a tender offer through its subsidiary Peach Purchaser Sub Inc. to acquire Pacira BioSciences for $36.50 per share in cash.
- Viatris to Acquire Pacira BioSciences for $1.65 Billion, Expanding Non-Opioid Pain Portfolio$1.6B · With Pacira BioSciences Inc.
- Harrow Closes Acquisition of TYRVAYA®Viatris Inc. has sold the worldwide rights (excluding Japan) for its TYRVAYA® nasal spray to Harrow for $30 million in cash, with potential for up to $70 million in additional milestone payments.
- Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea...Viatris announced that its drug WAKIX® (pitolisant) has received approval from Japan's Ministry of Health, Labour and Welfare for treating excessive daytime sleepiness associated with obstructive sleep apnea syndrome and for narcolepsy.
- Viatris Lifts 2026 Outlook After Strong Second QuarterViatris reported an adjusted EBITDA of $1.2 billion for the second quarter of 2026, up 8% operationally.
- VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape OutlookViatris anticipates the potential launch of its fast-acting meloxicam product.
- Viatris Announces Quarterly DividendViatris Inc. declared a quarterly dividend of $0.12 per share.
- Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive PatchViatris received U.S. FDA approval for Gwyn Lo, a new once-weekly combined hormonal contraceptive patch with low-dose estrogen.
Showing 10 of 15 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Viatris with the Signal API
One POST /v1/companies/enrich call with viatris.com returns Viatris news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"viatris.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Viatris news
What is the latest news on Viatris?
What is going on with Viatris?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .